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objectives. Adult patients with type 2 diabetes mellitus (T2DM) newly initiating 
treatment between January 1, 2010, and December 31, 2011, with either saxagliptin 
or sitagliptin were identified. A 1:1 propensity-matched sample of saxagliptin and 
sitagliptin patients was created to reduce any potential confounding. Propensity 
scores were generated based on demographic characteristics, comorbidities, disease 
severity and treatment patterns before the index date. Patients were required to 
have ≥ 6 months of continuous eligibility before (baseline period) and after (follow-
up period) treatment initiation. All outcomes were assessed based on an intent-to-
treat analysis in the 6-month follow-up period. Both overall and diabetes-specific 
charges were computed; breakdowns of medical and overall (medical plus phar-
macy) charges were compared. Appropriate univariate statistical tests were applied 
to the propensity-matched sample to examine differences in resource utilization 
outcomes. Results: A total of 8,438 and 23,155 patients initiated treatment with 
saxagliptin and sitagliptin, respectively. After matching, each cohort consisted of 
7,700 patients. Compared with sitagliptin, during the follow-up period, saxagliptin 
was associated with significantly lower (all p values ≤ 0.01) overall charges ($13,203 
± $28,391 vs. $14,258 ± $35,586), diabetes-related overall charges ($5,106 ± $12,129 vs. 
$5,402 ± $14,201), overall medical charges ($9,454 ± $27,616 vs. $10,502 ± $34,903), and 
diabetes-related medical charges ($3,389 ± $12,080 vs. $3,689 ± $14,161). Accordingly, 
saxagliptin was associated with a lower proportion of patients recording an inpa-
tient stay (6.6% vs. 8.1%; p= 0.001) or diabetes-related inpatient stay (4.6% vs. 5.4%; 
p= 0.025). ConClusions: Patients initiating saxagliptin treatment reported lower 
charges and lower hospitalization rates (overall and diabetes-related) compared 
with patients initiating sitagliptin.
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objeCtives: Wearable health monitoring devices have become increasingly avail-
able and allow for real-time tracking of clinical values. This research aims to assess 
the trends in continuous glucose monitor (CGM) uptake and to examine differences 
in costs and resource utilization following their initial use. Methods: Adults aged 
18-64 with a diagnosis for diabetes (ICD-9-CM 250.xx) and continuous enrollment 
in commercial insurance were identified from the Truven Health MarketScan 
databases (2008-2012). An initial procedure code for CGM (CPT 95250) at least one 
year after the initial diagnosis and the lack of a previous claim for CGM identi-
fied eligible subjects within each year from 2009-2011; the date of the qualifying 
CGM claim served as the index date. Costs and utilization for pharmacy, inpatient, 
emergency department, specialty, laboratory, and primary care services were com-
pared between each annual cohort and between the year prior to and following the 
index date. Results: From 2009 to 2011, the number of initial patients using CGM 
declined, from 1,001 to 770 (p-value for trend < 0.001). The total average costs to treat 
these patients increased between 2009 and 2010 before declining in 2011, mostly due 
to dramatic changes in costs related to outpatient pharmacy and inpatient services. 
Compared to before the CGM was placed, mean annual costs for primary care visits 
and laboratory services tended to decrease while the average number of primary 
care visits consistently and significantly declined (all p< 0.05). However, noticeably 
higher mean costs related to outpatient pharmacy services were accrued following 
CGM use in both 2009 and 2010. ConClusions: Devices such as CGM may benefit 
ongoing patient care by providing more regular insight to treatment progression 
and, in some cases, lead to more efficient care.
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objeCtives: As novel treatments for type II diabetes enter the market, there is a 
need to assess their long-term clinical and economic outcomes compared to cur-
rent treatments. These comparisons can assist decision-makers in determining 
the appropriate place in therapy. Our objective was to review the existing phar-
macoeconomic literature evaluating the cost-effectiveness and overall costs of 
treatment associated with liraglutide in type II diabetes. Methods: We identified 
English-language cost-effectiveness, cost-utility or cost analyses that compared 
liraglutide to one or more anti-diabetic agents via MEDLINE and EMBASE through 
March 1, 2013. Full text articles meeting the inclusion criteria were retrieved and 
information on the study design and results were abstracted. Costs were converted 
to 2012 US dollars in order to facilitate comparisons across studies. Results: A 
total of 3 cost comparison studies and 6 cost-utility studies were identified for 
inclusion. Across cost comparison studies, liraglutide treatment resulted in cost 
savings ranging from $1,075 to $1,298 (1.2 mg) and $1,162 to $2,147 (1.8 mg) over a 
10 year time horizon. Cost-utility analysis results reported base case ICERs ranging 
from $15,774 to $40,128/QALY for liraglutide 1.2 mg and $8,497 to $66,031/QALY 
for liraglutide 1.8 mg. Estimates were most sensitive to variations in time horizon 
and cardiovascular complication rates. Based on often cited cost-utility thresholds, 
liraglutide was determined to have a probability of being cost effective between 58% 
(liraglutide 1.8 mg vs. sitagliptin 100 mg) and 93% (liraglutide 1.2 mg vs. glimepiride 
4 mg). ConClusions: Liraglutide appears to be a cost-effective adjunct treatment 
for type II diabetes and may also be associated with a reduction in diabetes-related 
complication costs; however, ICER values are largely dependent on the duration of 
liraglutide treatment benefit and the time horizon of the analysis.
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performed to assess the association between CKD stages and HRU/costs. Results: 
The study identified 23,492 T2DM patients (mean age: 60.7 years; no CKD: 54.9%; 
stage 1: 7.1%; stage 2: 12.7%; stage 3A: 15.9%; stage 3B: 7.5%; stage 4: 1.8%). Patients 
with more advanced CKD stages were associated with greater odds of hospitaliza-
tion compared to those without CKD (odds ratio [95% confidence interval] (stage 
1: 1.14 [1.00−1.30]; stage 3A: 1.57 [1.43−1.72]; stage 3B: 1.84 [1.63−2.07]; stage 4: 2.66 
[2.16−3.28]) and ER visits (stage 3A: 1.25 [1.15−1.37]; stage 3B: 1.34 [1.19−1.51]; stage 
4: 1.55 [1.25−1.92]). Patients with CKD stage 1, 2, 3A, 3B, and 4 had total costs of 1.18, 
1.17, 1.44, 1.54, and 1.80 times of those without CKD (all p< 0.01). ConClusions: 
CKD in T2DM patients was associated with higher HRU and costs compared to those 
without CKD. Additionally, HRU and costs increased with more advanced stages 
of CKD. Prevention of CKD progression may help contain the economic burden.
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objeCtives: To assess the impact of diabetes on direct medical expenditures 
for visits and prescribed medications related to skin and soft tissue infections 
(SSTIs). Methods: Hospital inpatient, outpatient, office, and emergency room vis-
its and prescribed medications related to SSTIs were identified from the 2010 and 
2011 Medical Expenditure Panel Survey. Total SSTI costs per patient per year were 
calculated by summing overall costs of all SSTI medical events. Differences in mean 
and median SSTI costs between patients with and without diabetes were assessed 
with the Wilcoxon-Mann-Whitney and median two-sample tests. Results: We 
identified 1684 SSTI events from 438 patients, including 93 (21%) having diabetes. 
Events (761 to 923) and costs ($259,784.74 to $375,696.03) increased from 2010 to 2011. 
Patients with diabetes were older (61 vs. 47) and a greater percentage had public 
insurance (46% vs. 28%). Average SSTI costs per patient with diabetes in 2010 and 
2011 were: $135.84 (standard deviation [sd]= 259.72) and $873.59 (sd= 2275.98) for 
prescribed medicines, $8990.54 (sd= 9506.02) and $8590.86 (sd= 8685.70) for inpatient 
and emergency room, $706.61 (sd= 1729.25) and $1255.25 (sd= 3561.37) for outpa-
tient and office. Average SSTI costs per patient without diabetes in 2010 and 2011 
were: $143.91 (standard deviation [sd]= 411.68) and $46.71 (sd= 78.07) for prescribed 
medicines, $832.92 (sd= 1482.56) and $2431.65 (sd= 7758.02) for inpatient and emer-
gency room, $486.55 (sd= 1237.81) and $568.32 (sd= 1247.08) for outpatient and office. 
The mean total SSTI cost difference between patients with and without diabetes 
was $1627.93 ($2481.09-$853.16, p-value= 0.1441) in 2010 and $1065.60 ($2604.75-
$1539.15, p-value= 0.1789) in 2011. The median total SSTI cost difference per patient 
per year was $78.61 ($237.72-$159.11, p-value= 0.3948) and $38.21 ($237.00-$198.79, 
p-value= 0.2666). ConClusions: In a nationally representative sample, mean and 
median SSTI costs related to medical visits and prescriptions were higher among 
patients with diabetes, however these costs did not differ significantly compared 
to patients without diabetes.
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objeCtives: Identify, categorize the two year costs (insurer paid amount) of inten-
sive insulin treatment for patients diagnosed with type 2 diabetes. Focus on inten-
sively-treated patients receiving MDI (multiple daily injections of insulin) or CSII 
(continuous subcutaneous insulin infusion). Investigate and measure the spending 
by payers for these patients determine which related diagnosis contribute the most 
to the two year aggregate. Methods: Patients and their expenditures were identi-
fied retrospectively using administrative health care insurance claims from the 
2010 and 2011 edition of Truven MarketScan Commercial. Patients were identified 
as having type 2 diabetes based on diagnosis from these claims. Treatment groups 
were assigned from medical-surgical and drug benefit claims for insulin, an insulin 
pump or related supplies. Patients with a claim for type 1 diabetes, gestational dia-
betes, cancer, HIV/AIDS, trauma, organ transplants were excluded. Patients in the 
lowest or highest 99th cost percentile and patients without continuous enrollment 
for the entire period were excluded. Expenditures were segmented by benefit type 
and were stratified separately as “diabetes-related” if the claim’s primary ICD-9-CM 
code was related to diabetes. Conversely, claims with primary diagnosis codes not 
related to diabetes were classified as “not related to diabetes”. Results: After exclu-
sions, there were 20,355 patients identified as MDI and 481 patients identified as 
using CSII. For both groups, the majority of the total treatment expenditures were 
not related to diabetes. For patients in the same treatment cohort of the prior year 
(ie. 2011 vs. 2010), the proportion of expenditures were similar. ConClusions: 
For patients identified as MDI or CSII, non-diabetes related costs were the highest 
contributors to aggregate payer spending. Further analysis is needed to determine 
if other characteristics of the patients analyzed have an effect on the proportion 
of costs.
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objeCtives: To compare charges and resource use during the 6 months follow-
ing treatment initiation with saxagliptin or sitagliptin. Methods: A retrospective 
cohort study using a US insurance claims dataset was conducted to meet the study 
